Description
Scope of the Report The report titled “ Global Glaucoma Treatment Market : Trends and Opportunities ( 2015 Edition )” analyzes the potential opportunities , challenges , demand drivers and significant trends representing the Glaucoma treatment market . The report elucidates facts on the glaucoma treatment market as supplemented by the latest available statistics . It also profiles and analyzes the leading four companies operating in this industry with latest data and a brief overview of their business and financial performance along with a brief discussion of their future business strategies . The report gives valuable insight into technology used in glaucoma treatment market , its demand in various geographies . In the report , we also try to study the growth pattern in the prescriptions and revenue earned by the glaucoma treatment companies and the latest trends concerning glaucoma treatment market . Most importantly , we have analyzed the current market size and project future market size of the overall glaucoma treatment market for the years to come .
Request a sample of this report @ http :// www . orbisresearch . com / contacts / request-sample / 185298 .
Company Coverage Biolite Israeli Pfizer Inc . Merck & Co . Inc . Alcon ( A division of Novartis )
Products Covered Prostaglandin Combination Market Carbonic Anhydrase Inhibitor Beta Blocker Alpha Agonist & Cholinergic Surgical Devices
Purchase a copy of Global Glaucoma Treatment Market visit @ http :// www . orbisresearch . com / contact / purchase / 185298 For more information contact sales @ orbisresearch . com .
Executive Summary The global Glaucoma market has been growing rapidly since the past several years mainly due to innovation such as introduction of IOPtiMa , OTP-TX , anti-VEGF therapy , photodynamic therapy ( PDT ) laser photocoagulation , Rhopressa , latanoprost and Vesneo . Among the several varieties of drugs and surgeries available in the market , the demand for drugs such as Prostaglandins which includes Trabatan , Lumbigan are the highest due to its high efficiency in treating glaucoma . Vesneo has shown a superior intraocular pressure reduction effect on beta-blocker timolol , the most widely used comparator in registration trials for glaucoma , in two phase 3 studies .
www . orbisresearch . com ; + 1 ( 214 ) 884-6817 ; + 9120-64101019